Skip to main content

BEYFORTUS (Sanofi-Aventis Australia Pty Ltd)

Product name
Date registered
Evaluation commenced
Decision date
Approval time
200 (255 working days)
Active ingredients
Registration type

BEYFORTUS is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in:

  • Neonates and infants born during or entering their first RSV season.
  • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

BEYFORTUS should be used in accordance with official recommendations.

Help us improve the Therapeutic Goods Administration site